Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in developing innovative tests to guide patient care, will present new data on the clinical performance of its DecisionDx®-Melanoma and MyPath® Melanoma tests at the 61st Annual Meeting of the American Society of Dermatopathology (ASDP). The event will take place from November 7-10 in Chicago.
“We are committed to advancing evidence development to show how our tests can support clinical decision-making,” said Rebecca Critchley-Thorne, Ph.D., Vice President of Research and Development at Castle Biosciences. “The data we will present at ASDP highlight the ability of our tests to accurately risk-stratify patients with confirmed or suspected melanoma, helping clinicians make more informed decisions about treatment and management.”
Castle’s posters at the meeting will be presented by Etan Marks, D.O., a board-certified dermatopathologist and laboratory director at Advanced Dermatology and Cosmetic Surgery in Delray Beach, Florida. Marks will present during a two-hour poster defense session on Saturday, Nov. 9, from 3:30-5:30 p.m. Central time in the Chicago Ballroom (5th floor).
Posters Presented at ASDP
DecisionDx-Melanoma
Poster 231: The integrated 31-gene expression profile test stratifies recurrence risk within cutaneous melanoma subtypes
MyPath Melanoma
Poster 232: Appropriate statistical methods to assess cross-study diagnostic 23-gene expression profile test performance for cutaneous melanocytic neoplasms
About DecisionDx®-Melanoma
DecisionDx-Melanoma is a gene expression profile test designed to assess the risk of sentinel lymph node positivity and the likelihood of melanoma recurrence or metastasis in patients with cutaneous melanoma. The test combines tumor biology with clinical and pathological factors using a proprietary algorithm, providing comprehensive and actionable results to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples.
With over 50 peer-reviewed studies supporting its clinical value, DecisionDx-Melanoma is trusted by clinicians to guide disease management. As of September 30, 2024, the test has been ordered approximately 183,000 times for patients diagnosed with cutaneous melanoma.
About MyPath® Melanoma
MyPath Melanoma is a gene expression profile test designed to help dermatopathologists and dermatologists accurately characterize challenging melanocytic lesions. Among the approximately two million pigmented lesions biopsied annually in the U.S., Castle estimates that around 300,000 cannot be definitively classified as either benign or malignant using traditional histopathology methods. For these cases, the treatment plan may be uncertain.
By providing an accurate, objective result, MyPath Melanoma helps reduce diagnostic uncertainty, ensuring more informed management decisions for patients. The test is used in conjunction with other clinical and histopathologic information to provide confidence for dermatopathologists and assist dermatologists in delivering precise care.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. The company’s portfolio includes tests for skin cancers, Barrett’s esophagus, mental health conditions, and uveal melanoma, with ongoing research and development programs for tests in other high-need areas, including a test to guide systemic therapy selection for patients with atopic dermatitis, psoriasis, and related conditions.
Castle’s mission is to transform disease management by keeping patients, clinicians, employees, and investors at the forefront of everything they do.
